ShoreCap says GSK has cracked it and the £40bn prize is now in sight

Shore Capital argues GSK has effectively met its FY21–26 targets a year early after solid full-year results and operational progress (five FDA approvals, seven pivotal trials, four acquisitions, ten licensing deals), and reiterates a Buy with a 2,500p fair value. The broker lifts its 2031 revenue target to £40bn (from £38bn), cites Specialty Medicines as the growth engine (17% CC growth in FY25; Shore forecasts ~15% for FY26 vs company low double-digit guidance), and notes FX weakens FY26 sales by ~2% and EPS by ~5% near-term. Valuation now implies ~14x FY26 and ~12x FY27 earnings, which Shore views as undemanding versus large-cap pharma peers.

Analysis

Market structure: Shore’s thesis reallocates growth to Specialty Medicines (oncology, HBV, metabolic) making GSK (LSE: GSK / NYSE: GSK) a direct beneficiary while Vaccines and General Medicines peers face headwinds from CDC guidance and US pricing pressure. Expect market share gains in high-value oncology niches (Bl enrep/Exdensur rollouts) and higher pricing power in specialty segments; near-term supply/demand tightness for niche biologics could keep ASPs elevated. Cross-asset: equity upside should compress GSK credit spreads (supporting bonds), reduce implied equity volatility, while a weaker USD remains a two-way FX risk that can trim reported sales by ~2% and EPS by ~5% as Shore models suggest.

Risk assessment: Key tail risks are binary trial/regulatory failures (HBV functional cure, label expansions for Blenrep) and faster-than-expected HIV revenue erosion if replacements underperform — both would remove Shore’s upside. Timeframe: immediate (days) = sentiment lift; short-term (3–9 months) = consensus upgrades/earnings revisions and FX-driven EPS updates; long-term (2026–2031) execution on pipeline to reach ~£40bn revenue. Hidden dependency: trajectory hinges on two drugs hitting >£3bn peak each; if combined Specialty growth <10% in FY26, de-rate quickly. Catalysts: upcoming pivotal readouts and label decisions in next 12–24 months.

Trade implications: Tactical long GSK exposure is attractive with risk-managed sizing: Shore’s 2,500p target implies ~+30–50% upside vs many current levels—establish 2–3% position, target 2,500p within 12–24 months, stop if FY26 EPS misses consensus by >7% or Specialty growth <10%. Pair trade: long GSK vs short AstraZeneca (AZN) or PFE to isolate specialty execution; options: buy 12-month LEAP call spread 25%/50% OTM sized to 1% notional and fund by selling 6–9 month 15% OTM puts. Rotate away from vaccine/CHC names under CDC pressure into specialty-biotech ETFs and large-cap specialty pharma.

Contrarian angles: The market may under-price the binary risk of HBV/oncology outcomes and over-credit management’s ability to replace HIV revenue — Shore’s £40bn assumes multiple high-probability wins that historically have 30–60% clinical success. Historical parallels: pharma turnarounds (e.g., Roche oncology cadence) show that execution is multi-year; unintended consequence: management may pursue M&A at higher prices, raising leverage — re-evaluate if net debt/EBITDA >3.5x. Watch for rapid sentiment reversal on any negative pivotal readout within 6–18 months.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (LSE: GSK / NYSE: GSK) sized by portfolio risk budget, target Shore’s 2,500p fair value within 12–24 months, set hard stop if FY26 EPS misses consensus by >7% or Specialty revenue growth <10% YoY.
• Implement a relative-value pair: long GSK (1%) vs short AZN (1%) to isolate GSK specialty execution; rebalance if divergence >15% or after next quarterly results.
• Buy a 12–18 month LEAP call spread (buy 25% OTM / sell 50% OTM) sized to ~1% notional and finance by selling 6–9 month 15% OTM puts to collect premium; roll/trade if implied vol falls >30% or after positive pivotal readouts.
• Reduce/avoid exposure to vaccine/consumer-health names (e.g., vaccine-heavy and CHC-exposed tickers) by 2–4% and rotate into specialty pharma/biotech ETFs (or direct large-cap specialty names) given near-term headwinds and longer-term specialty tailwinds.
• Monitor three catalysts over the next 12 months—(1) pivotal HBV readouts, (2) Blenrep/Exdensur label expansions or sales cadence, (3) FX moves—reassess if combined Specialty sales guidance slips by >15% vs current consensus or if net debt/EBITDA breaches 3.5x.